JB/CALL/MERCK & CO./130/0.0333/20.09.24 Stock

MRKAJB

CH1257352083

Market Closed - Swiss Exchange 11:20:00 2024-06-27 am EDT
0.17 ^CHF	-29.17%

Current month	+21.43%
1 month	-15.00%

Comparison chart between the derivative product and it's underlying value

End-of-day quotes

Chart MERCK & CO., INC.

Chart JB/CALL/MERCK & CO./130/0.0333/20.09.24

Latest news about MERCK & CO., INC.

CDC’S ACIP Unanimously Recommends Merck’s CAPVAXIVE™ (Pneumococcal 21-valent Conjugate Vaccine) for Pneumococcal Vaccination in Appropriate Adults	08:19pm	BU
Merck : CDC’s ACIP Unanimously Votes to Add Merck and Sanofi’s Pediatric Hexavalent Combination Vaccine to its Preferential Recommendation to Help Prevent Invasive Hib Disease in American Indian and Alaska Native Infants - Merck.com	Jun. 27	PU
Merck - Patritumab Deruxtecan BLA Submission Receives Complete Response Letter from FDA Due to Inspection Findings at Third-Party Manufacturer	Jun. 27	AQ
FDA Turns Away Daiichi Sankyo, Merck Lung-Cancer ADC	Jun. 27	DJ

More news

Quotes 5-day view

Date	Price	Change
24-06-27	0.17	-29.17%
24-06-25	0.24	+9.09%
24-06-24	0.22	+29.41%
24-06-21	0.17	+6.25%
24-06-20	0.16	+6.67%

Delayed Quote Swiss Exchange

Last update June 27, 2024 at 11:20 am EDT

More quotes

Static data

Product type	Plain-Vanilla-Warrants
Buy / Sell	CALL
Underlying	MERCK & CO., INC.
Issuer	Bank Julius Bär
	MRKAJB
ISIN	CH1257352083
Date issued	2023-04-12
Strike	130 $
Maturity	2024-09-20 (85 Days)
Parity	30 : 1
Emission price	0.25 CHF
Emission volume	N/A
Settlement	cash
Currency	CHF

Technical Indicators

Highest since issue	0.3 CHF
Lowest since issue	0.03 CHF
Spread	0.01 CHF
Spread %	5.88%

Company Profile

Merck & Co., Inc. specializes in the development, production, and marketing of therapeutic products and vaccines sold under prescription. Net sales break down by activity as follows: - sale of pharmaceutical products (69.7%): for treating hypertension, osteoporosis, atherosclerosis, respiratory, bacterial and fungal, ophthalmologic, and urological diseases, acute migraine, hair loss in men, etc.; - sale of vaccines (18%); - sale of animal health products (9.4%); - other (2.9%). Net sales are distributed geographically as follows: the United States (45.9%), Europe/Middle East/Africa (24.5%), China (8.8%), Japan (6.1%), Asia/Pacific (6.1%), Latin America (4.3%) and other (4.3%).

Sector

More about the company

Ratings for Merck & Co., Inc.

Trading Rating

Investor Rating

ESG Refinitiv

B-

More Ratings

Consensus: Merck & Co., Inc.

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

129.8 USD

Average target price

142.7 USD

Spread / Average Target

+9.91%

Consensus